|
EP1776383B1
(en)
|
2004-07-22 |
2014-08-20 |
Erasmus University Medical Center Rotterdam |
Binding molecules
|
|
TWI404727B
(zh)
*
|
2006-01-25 |
2013-08-11 |
荷蘭鹿特丹Erasmus大學醫學中心 |
對偶基因排除
|
|
PL2346994T3
(pl)
|
2008-09-30 |
2022-04-19 |
Ablexis, Llc |
Myszy knock-in do wytwarzania chimerycznych przeciwciał
|
|
KR101711222B1
(ko)
|
2008-12-18 |
2017-02-28 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
DK3241435T3
(da)
|
2009-07-08 |
2021-08-23 |
Kymab Ltd |
Dyremodeller og terapeutiske molekyler
|
|
WO2011072204A1
(en)
|
2009-12-10 |
2011-06-16 |
Regeneron Pharmaceuticals, Inc. |
Mice that make heavy chain antibodies
|
|
PL3248462T3
(pl)
|
2010-03-31 |
2024-07-08 |
Ablexis, Llc |
Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
|
|
EP2601298B1
(en)
|
2010-08-02 |
2016-11-30 |
Regeneron Pharmaceuticals, Inc. |
Mice that make binding proteins comprising vl domains
|
|
JP2014505698A
(ja)
*
|
2011-02-02 |
2014-03-06 |
グラクソ グループ リミテッド |
新規抗原結合タンパク質
|
|
CN105861548B
(zh)
|
2011-02-25 |
2020-01-10 |
瑞泽恩制药公司 |
Adam6小鼠
|
|
ES2872081T3
(es)
|
2011-08-05 |
2021-11-02 |
Regeneron Pharma |
Ratones con cadena ligera universal humanizada
|
|
AU2012311286B2
(en)
|
2011-09-19 |
2018-07-26 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
WO2013041845A2
(en)
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Animals, repertoires & methods
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
EP4074833A1
(en)
|
2011-10-17 |
2022-10-19 |
Regeneron Pharmaceuticals, Inc. |
Restricted immunoglobulin heavy chain mice
|
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
SMT201900296T1
(it)
|
2011-12-20 |
2019-07-11 |
Regeneron Pharma |
Topi di catena leggera umanizzata
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
SG11201405059XA
(en)
|
2012-03-28 |
2014-09-26 |
Kymab Ltd |
Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
NZ703689A
(en)
*
|
2012-06-12 |
2016-05-27 |
Regeneron Pharma |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
|
RS57582B1
(sr)
|
2013-02-20 |
2018-11-30 |
Regeneron Pharma |
Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
|
|
PL2967012T3
(pl)
|
2013-03-14 |
2021-04-19 |
Erasmus University Medical Center Rotterdam |
Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
|
|
WO2014144495A1
(en)
|
2013-03-15 |
2014-09-18 |
Abvitro, Inc. |
Single cell bar-coding for antibody discovery
|
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
GB201316644D0
(en)
|
2013-09-19 |
2013-11-06 |
Kymab Ltd |
Expression vector production & High-Throughput cell screening
|
|
WO2015049517A2
(en)
|
2013-10-01 |
2015-04-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US20180169117A1
(en)
*
|
2014-03-20 |
2018-06-21 |
Otsuka Pharmaceutical Co., Ltd. |
Pharmaceutical formulation comprising a substituted phenyl - (1,3-dihydro-isoindol-2-yl) - methanone
|
|
SG10201808083VA
(en)
|
2014-03-21 |
2018-10-30 |
Regeneron Pharma |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
AU2015230938C1
(en)
|
2014-03-21 |
2021-10-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
US10590483B2
(en)
|
2014-09-15 |
2020-03-17 |
Abvitro Llc |
High-throughput nucleotide library sequencing
|
|
WO2016062988A1
(en)
*
|
2014-10-22 |
2016-04-28 |
Crescendo Biologics Limited |
Vh scaffold
|
|
WO2016062989A1
(en)
*
|
2014-10-22 |
2016-04-28 |
Crescendo Biologics Limited |
Human vh domain scaffolds
|
|
CN104710528B
(zh)
*
|
2015-03-13 |
2019-02-15 |
西北农林科技大学 |
一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用
|
|
CN107438622A
(zh)
|
2015-03-19 |
2017-12-05 |
瑞泽恩制药公司 |
选择结合抗原的轻链可变区的非人动物
|
|
US11306139B2
(en)
*
|
2015-03-20 |
2022-04-19 |
Ablynx N.V. |
Glycosylated immunoglobulin single variable domains
|
|
CA2981077A1
(en)
*
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
|
RU2749674C2
(ru)
|
2015-07-29 |
2021-06-16 |
Аллерган, Инк. |
Антитела против ang-2, содержащие только тяжелую цепь
|
|
EP3334762A1
(en)
|
2015-08-14 |
2018-06-20 |
Allergan, Inc. |
Heavy chain only antibodies to pdgf
|
|
AU2016332900C1
(en)
|
2015-09-29 |
2024-07-04 |
Amgen Inc. |
ASGR inhibitors
|
|
CN105777894A
(zh)
*
|
2016-03-12 |
2016-07-20 |
长春力太生物技术有限公司 |
通过转基因啮齿类动物制备人源化驼类单域抗体的方法
|
|
JP2019513415A
(ja)
*
|
2016-04-04 |
2019-05-30 |
イーティーエッチ チューリッヒ |
タンパク質産生及びライブラリー生成のための哺乳類細胞株
|
|
IL299221A
(en)
|
2016-06-21 |
2023-02-01 |
Teneobio Inc |
Cd3 binding antibodies
|
|
CN109862784A
(zh)
*
|
2016-08-24 |
2019-06-07 |
特尼奥生物股份有限公司 |
产生经修饰的仅有重链的抗体的转基因非人动物
|
|
CR20220578A
(es)
|
2016-09-14 |
2023-01-17 |
Teneobio Inc |
Anticuerpos de unión a cd3
|
|
WO2018069480A1
(en)
*
|
2016-10-14 |
2018-04-19 |
Institut Curie |
New anti-lsp1 antibody
|
|
CN109906030B
(zh)
*
|
2016-11-04 |
2022-03-18 |
安健基因公司 |
用于产生仅重链抗体的经基因修饰的非人动物和方法
|
|
EP3559035A1
(en)
*
|
2016-12-21 |
2019-10-30 |
TeneoBio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
US11267904B2
(en)
|
2016-12-28 |
2022-03-08 |
Sysmex Corporation |
Method for controlling affinity of antibody for antigen, antibody whose affinity for antigen has been altered, and its production method
|
|
CA3050715A1
(en)
*
|
2017-01-19 |
2018-07-26 |
Open Monoclonal Technology, Inc. |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
JP7240335B2
(ja)
*
|
2017-06-20 |
2023-03-15 |
テネオワン, インコーポレイテッド |
抗bcma重鎖のみ抗体
|
|
CN110891971B
(zh)
*
|
2017-06-20 |
2024-01-12 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
GB201710984D0
(en)
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|
|
US20200207867A1
(en)
|
2017-09-13 |
2020-07-02 |
Teneobio, Inc. |
Heavy chain antibodies binding to ectoenzymes
|
|
SG11202005692WA
(en)
*
|
2017-12-20 |
2020-07-29 |
Harbour Biomed Shanghai Co Ltd |
Antibodies binding ctla-4 and uses thereof
|
|
EA202091557A1
(ru)
|
2017-12-22 |
2020-11-18 |
Тенеобио, Инк. |
Антитела, содержащие только тяжелые цепи, которые связываются с cd22
|
|
SG11202004158QA
(en)
|
2017-12-28 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against tigit
|
|
ES3076179T3
(en)
*
|
2018-03-21 |
2026-08-12 |
Crystal Bioscience Inc |
Transgenic chicken that produces human antibodies
|
|
AU2019241350B2
(en)
|
2018-03-30 |
2025-10-02 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
|
JP7572861B2
(ja)
|
2018-06-13 |
2024-10-24 |
クリスタル バイオサイエンス インコーポレイテッド |
遺伝子変換による自律型重鎖可変ドメインの改変による抗体の産生
|
|
CA3102125A1
(en)
*
|
2018-06-13 |
2019-12-19 |
Crystal Bioscience Inc. |
Transgenic chicken that makes antibodies with long cdr-h3s stabilized by multiple disulfide bridges and diversified by gene conversion
|
|
LT3823990T
(lt)
|
2018-07-20 |
2026-04-10 |
TeneoTwo, Inc. |
Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
|
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
WO2020087065A1
(en)
|
2018-10-26 |
2020-04-30 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd38
|
|
CN113874394B
(zh)
|
2019-02-20 |
2024-01-19 |
和铂抗体有限公司 |
抗体
|
|
CA3133654A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
US20220227888A1
(en)
|
2019-06-07 |
2022-07-21 |
Amgen Inc. |
Bispecific binding constructs with selectively cleavable linkers
|
|
CN114206927B
(zh)
|
2019-06-14 |
2025-03-21 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
BR112022011824A2
(pt)
|
2019-12-18 |
2022-08-30 |
Teneofour Inc |
Anticorpos de cadeia pesada que se ligam a cd38
|
|
GB202003632D0
(en)
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
|
KR20250007022A
(ko)
|
2020-04-29 |
2025-01-13 |
테네오원, 인코포레이티드 |
변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
|
|
CA3184351A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Bispecific binding constructs
|
|
EP4545569A3
(en)
|
2020-06-30 |
2025-10-08 |
Harbour Biomed (Shanghai) Co., Ltd |
Binding protein having h2l2 and hcab structures
|
|
WO2022002036A1
(zh)
|
2020-06-30 |
2022-01-06 |
和铂医药(上海)有限责任公司 |
一种双特异性抗体及其用途
|
|
IL299027A
(en)
|
2020-06-30 |
2023-02-01 |
Teneobio Inc |
Multispecific antibodies that bind BCMA
|
|
US20220090060A1
(en)
|
2020-09-11 |
2022-03-24 |
Regeneron Pharmaceuticals, Inc. |
Identification and production of antigen-specific antibodies
|
|
GB202017555D0
(en)
|
2020-11-06 |
2020-12-23 |
Harbour Antibodies Bv |
Antibody-conjugated nanoparticles
|
|
TW202233684A
(zh)
|
2020-11-18 |
2022-09-01 |
美商泰尼歐生物公司 |
結合於葉酸受體α之重鏈抗體
|
|
MX2023006573A
(es)
|
2020-12-03 |
2023-06-19 |
Amgen Inc |
Constructos de inmunoglobulina con multiples dominios de union.
|
|
EP4241789A4
(en)
|
2020-12-08 |
2025-04-02 |
Nona Biosciences (Shanghai) Co., Ltd. |
Protein-drug conjugate and site-specific conjugation method
|
|
JP7822400B2
(ja)
*
|
2020-12-09 |
2026-03-02 |
トリアンニ,インコーポレーテッド |
重鎖のみ抗体
|
|
EP4262373A1
(en)
|
2020-12-16 |
2023-10-25 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized fc alpha receptors
|
|
WO2022183074A2
(en)
|
2021-02-25 |
2022-09-01 |
Teneobio, Inc. |
Anti-psma antibodies and car-t structures
|
|
MX2023009882A
(es)
|
2021-02-26 |
2023-08-30 |
Teneobio Inc |
Anticuerpos anti-muc1-c y estructuras car-t.
|
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗il-2r抗體及使用方法
|
|
PE20260568A1
(es)
|
2021-04-06 |
2026-03-10 |
Teneobio Inc |
Anticuerpos anti-cd19 y estructuras car-t
|
|
CN117337303A
(zh)
|
2021-04-16 |
2024-01-02 |
特尼奥生物股份有限公司 |
抗cd20抗体及car-t结构
|
|
EP4333614A4
(en)
*
|
2021-05-05 |
2025-04-09 |
Leveragen, Inc. |
MANIPULATED NON-HUMAN ANIMALS TO PRODUCE ANTIBODIES
|
|
WO2022271987A1
(en)
|
2021-06-23 |
2022-12-29 |
TeneoFour, Inc. |
Anti-cd38 antibodies and epitopes of same
|
|
WO2023004197A1
(en)
|
2021-07-23 |
2023-01-26 |
Teneoten, Inc. |
Heavy chain antibodies binding to hepatitis b surface antigen
|
|
WO2023036982A1
(en)
|
2021-09-10 |
2023-03-16 |
Harbour Antibodies Bv |
Anti-sars2-s antibodies
|
|
GB202112935D0
(en)
|
2021-09-10 |
2021-10-27 |
Harbour Antibodies Bv |
Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
|
|
US20250215089A1
(en)
|
2022-04-02 |
2025-07-03 |
Harbour Biomed (Shanghai) Co., Ltd |
Antigen-binding protein targeting pd-l1 and cd40, preparation therefor, and use thereof
|
|
WO2023246578A1
(zh)
*
|
2022-06-24 |
2023-12-28 |
成都科伦精准生物科技有限公司 |
特异性结合gpc3的嵌合抗原受体及其应用
|
|
EP4598958A1
(en)
|
2022-10-05 |
2025-08-13 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
WO2024186634A2
(en)
*
|
2023-03-03 |
2024-09-12 |
Binacea Pharma, Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
|
EP4512243A1
(en)
|
2023-08-21 |
2025-02-26 |
Kymab Limited |
Binding molecules
|
|
WO2025042968A1
(en)
*
|
2023-08-22 |
2025-02-27 |
Integral Molecular, Inc. |
Compositions and methods related to chicken recombinant heavy-chain only antibodies
|
|
GB202406483D0
(en)
|
2024-05-09 |
2024-06-26 |
Harbour Antibodies Bv |
Crossing the blood brain barrier to treat diseases of the brain
|
|
WO2026030428A2
(en)
|
2024-08-01 |
2026-02-05 |
Regeneron Pharmaceuticals, Inc. |
Prostate-specific antigen peptides and uses thereof
|
|
US20260123608A1
(en)
|
2024-08-06 |
2026-05-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
|
|
WO2026096736A1
(en)
|
2024-10-31 |
2026-05-07 |
Regeneron Pharmaceuticals, Inc. |
Rodents expressing humanized polymeric immunoglobulin receptor
|